ArticleRNA (New York, N.Y.)2019
Sequence-specific m
Article in RNA (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- A versatile type VI CRISPR-based approach for targeted mGenome research · 2026Article
- Biological roles of enhancer RNA m6A modification and its implications in cancer.Cell communication and signaling : CCS · 2025Review
- Targeting mCurrent oncology (Toronto, Ont.) · 2025Review
- Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Precision Transcriptome Editing.ACS synthetic biology · 2024Review
- Dynamic multilayered control of mProceedings of the National Academy of Sciences of the United States of America · 2024Article
- CRISPR/dCas13(Rx) Derived RNA NAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Progression of mCell death discovery · 2024Review
- Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.Nature chemical biology · 2024Review
- Epigenetic and epitranscriptomic regulation during oncogenicFrontiers in microbiology · 2024Review
- The rise of epitranscriptomics: recent developments and future directions.Trends in pharmacological sciences · 2024Review
- The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches.Cancers · 2023Review
- The role of regulators of RNA mGenes & diseases · 2023Review
- Crosstalk among mJournal of hematology & oncology · 2022Review
- N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma.Scientific reports · 2022Article
- m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential.Frontiers in genetics · 2022Review
- The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.Frontiers in oncology · 2022Review
- Programmable technologies to manipulate gene expression at the RNA level.Current opinion in chemical biology · 2021Review
- Harnessing self-labeling enzymes for selective and concurrent A-to-I and C-to-U RNA base editing.Nucleic acids research · 2021Article
- Controlling Site-Directed RNA Editing by Chemically Induced Dimerization.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.